Completing the Molecular Workup: Mutations, PRAME, and the Case for Early HLA Testing

In this segment, our panel goes deeper into the molecular workup for uveal melanoma, covering the prognostic significance of BAP1, SF3B1, and EIF1AX mutations alongside gene expression profiling, and explaining how PRAME is emerging as both a prognostic marker and a potential therapeutic target. You will also hear why HLA-A*02:01 testing has become one of the most important tests you can order for any uveal melanoma patient, not as a prognostic marker but as a predictive one that determines eligibility for the only therapy with a demonstrated overall survival benefit in this disease. The panel makes a compelling case for ordering HLA typing at primary diagnosis rather than waiting for metastatic disease, drawing a direct parallel to the role BRAF testing plays in cutaneous melanoma.